Lecture 15 - Lipid Lowering Drugs Flashcards

1
Q

Type 1 Familial dislipidemia (aka Hyperchylomicronemia) is the only Familial dislipidemia that doesn’t do what? This Dislipidemia causes elevated _______.

A

Increase risk of CAD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Type II Familial Dislipidemia (aka _______) patients typically have MIs before ___ years of age, and present with tendon ______ and Corneal Arcus.

A

Hypercholesterolemia

20

Tendon Xanthoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Type III Familial dyslipidemia (aka Dysbetaproteinemia) causes elevated _____ AND _____. Look for Palmar ______ in these patients.

A

Triglycerides and Cholesterol

Palmar Xanthomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Type IV is Hypertriglyceridemia that causes acute ______.

A

Pancreatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Statins work to decrease the production of Cholesterol by inhibiting _____-_____ reductase, and they upregulate _____ receptors (thus removing more from the blood.)

A

HMG-CoA reductase

LDL recetors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

_______ is the only statin that does not compete for the CYP liver enzymes.

A

Pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

_______ is the statin with the longest lasting effect on HMG-CoA reductase (about 20hrs from a single dose.)

A

Atorvistatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

If liver enzymes are > ___ times their normal value, statins should be discontinued.

A

> 3 times

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

The risk of ______ from statins is higher in patients who are also taking Fibrates and Nicotinic acid.

A

Myopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Statin metabolism is inhibited by anti-______ medications and is accelerated by Barbituates, carbamazepine, rifampin, and phenytoin.

A

anti-Fungal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bile sequestrants help to lower cardiac events, but they have the consistency of sand, and they may increase serum ______. Also, they have a TON of drug interactions.

A

Triglycerides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Niacin lowers lipids via inhibition of _______ secretion. It is a nicotinic acid, and is among the few meds that will INCREASE _____ levels (and it does so to the greatest degree.)

A

VLDL

HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Majority of patients that take niacin experience intense _______ and pruritis of the face and upper body. It is orally bioavailable and has a short half-life. It is not a great medication for diabetics bc it may increase ______ levels, and it may increase ____ acid levels (so not good for patients with gout either).

A

Flushing

Glucose

Uric acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Fibrates upregulate ______ lipase, so there’s increased clearance of VLDL. It also decreases expression of ___ C-IIII, which is an LPL inhibitor. They also increase _____ acid oxidation.

A

Lpoprotein lipase

APO C-III

Fatty acid oxidation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Fibrate side effects include increased myopathy in patients who are also taking statins, and _______ - gall stones - (so don’t give it to obese and Native American patients).

A

Cholelithiasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ezetimibe is an inhibitor of luminal _______ uptake by enterocytes. It has the benefit of being well tolerated.

A

Cholesterol uptake

17
Q

Lomitapide and Mipomersen are used ONLY for the treatment of _______ (homo or heterozygous?) Familial Hypercholesterolemia.

A

Homozygous

18
Q

______ inhibitors are used to treat Heterozygous Familial Hypercholesterolemia. Evolocumab and Alirocumab are the generic names of these meds, and they act by increasing the number of ____ receptors on hepatocyte cell membranes.

A

PCSK9 inhibitors

LDL receptors